Theramir Ltd has recently been awarded a grant from the Research Promotion Foundation (RPF) in collaboration with the Cyprus University of Technology (CUT) and the National Technical University of Athens (NTUA) to further advance its proprietary microRNA-based therapeutics targeted against specific proteins (oncoproteins) in cancer. The project will investigate a metastasis-specific miRNA biomarker and will develop Theramir’s therapeutic agents to target both primary tumors and metastatic focii in an animal model of breast cancer (breast to brain model). The project (acronym: MICROCURE) is funded through the RPF program call Didaktor, with a duration of 30 months and a total budget of €159,442.